Ravulizumab and other complement inhibitors for the treatment of autoimmune disorders
- DOI
- 10.1016/j.msard.2025.106311
- Published
- 2025-03
- Container
- Multiple Sclerosis and Related Disorders
- Publisher
- Elsevier BV
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.1016/j.msard.2025.106311,
title = {Ravulizumab and other complement inhibitors for the treatment of autoimmune disorders},
author = {Gabriel de Deus Vieira and Vinícius Oliveira Boldrini and Simone Mader and Tania Kümpfel and Edgar Meinl and Alfredo Damasceno},
year = {2025},
journal = {Multiple Sclerosis and Related Disorders},
doi = {10.1016/j.msard.2025.106311},
url = {https://doi.org/10.1016/j.msard.2025.106311}
}RIS
TY - JOUR TI - Ravulizumab and other complement inhibitors for the treatment of autoimmune disorders AU - Gabriel de Deus Vieira AU - Vinícius Oliveira Boldrini AU - Simone Mader AU - Tania Kümpfel AU - Edgar Meinl AU - Alfredo Damasceno PY - 2025 JO - Multiple Sclerosis and Related Disorders DO - 10.1016/j.msard.2025.106311 UR - https://doi.org/10.1016/j.msard.2025.106311 ER -
APA
Vieira, G. D. D., Boldrini, V. O., Mader, S., Kümpfel, T., Meinl, E., & Damasceno, A. (2025). Ravulizumab and other complement inhibitors for the treatment of autoimmune disorders. Multiple Sclerosis and Related Disorders. https://doi.org/10.1016/j.msard.2025.106311
Source records
- crossref · retrieved 2026-09-26T04:18:26.360Z